FDA lifts partial clinical hold on Zentalis Pharma's cancer WEE1 inhibitor [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Yahoo! Finance
Zentalis Pharmaceuticals' azenosertib, allowing the company to continue evaluating the drug as a treatment for cancer. Following the FDA decision, Zentalis' stock was up by 53%, from $3.24 at closing on 13 September to $4.96 at the market opening on 16 September. In an announcement, Zentalis's CEO Kimberly Blackwell said: “Our confidence in the therapeutic index of azenosertib has been unwavering, and we continue to believe in the potential for this treatment to address unmet medical needs faced by people living with gynecologic malignancies.” The FDA placed the partial hold on three studies investigating azenosertib in June 2024 following the death of two trial participants. Azenosertib was being investigated in solid tumours in a Phase I study (NCT04158336) and more specifically in patients with ovarian (NCT05128825) and uterine cancer (NCT04814108) in two Phase II studies. Two patients in the ovarian cancer study died due to presumed blood-related infection associated with th
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLPR Newswire
- Zentalis Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZNTLAccesswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLPR Newswire
- ZNTL STOCK ALERT: Levi & Korsinsky Notifies Zentalis Pharmaceuticals, Inc. Investors of an Ongoing InvestigationAccesswire
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ZNTL
Earnings
- 11/12/24 - Beat
ZNTL
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form 4
- 2/11/25 - Form 144
- ZNTL's page on the SEC website